1
Return

Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies—United States, 2017–March 2020

delete2026-07-08
delete0
delete
OA
AI
C
Chelsea S Lutz, PhD, MPH
P
Patricia Castro-Roman, MPH
M
Mona Marin, MD
B
Brian Wakeman, PhD
S
Stephen N Crooke, PhD
E
Elina El-Badry, PhD
N
Nicole A Escudero Gonzalez, MS
T
Thomas D Filardo, MD
Z
Zhizhou Kuang, PhD
D
Daniel L Joo, MS
T
Tatiana M Lanzieri, MD
S
Sara E Oliver, MD, MPH
E
Eriko Padron-Regalado, PhD
D
David E Sugerman, MD, MPH
J
Jamie Tappe, MPH
P
Paul A Rota, PhD
T
Tara C Anderson, DVM, MPH, PhD *
DOI：10.1093/infdis/jiag354delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
The most recent assessment of antibodies against measles, mumps, rubella, and varicella-zoster viruses (MeV, MuV, RuV, VZV) in the United States was conducted in 2009–2010. Regular assessments are essential to measure the impact of immunization programs, identify immunity gaps, and inform vaccination strategies. We report updated estimates of national seroprevalence.

Journal

T
The Journal of Infectious Diseases
IF:
0
Papers:
242
Citations:
0

Organization

C
centers for disease control and prevention
Scholars:
1.1K
Papers: 260
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers